SE445680B - Immunoanalysforfarande och anordning for bestemning av obundna substanser - Google Patents

Immunoanalysforfarande och anordning for bestemning av obundna substanser

Info

Publication number: SE445680B
Authority: SE; Sweden
Prior art keywords: substance; antibody; analog; microcapsules; sample
Prior art date: 1978-06-20

Application number

SE7905101A

Other languages

English (en)

Swedish (sv)

Other versions

SE7905101L (sv

Inventor

F Lim

R D Moss

R J Buehler

T H Chan

Original Assignee

Damon Biotech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1978-06-20

Filing date

1979-06-12

Publication date

1986-07-07

1978-11-27 Priority claimed from US05/963,932 external-priority patent/US4255411A/en

1979-06-12 Application filed by Damon Biotech Inc filed Critical Damon Biotech Inc

1979-12-21 Publication of SE7905101L publication Critical patent/SE7905101L/

1986-07-07 Publication of SE445680B publication Critical patent/SE445680B/sv

Links

239000000126 substance Substances 0.000 title claims description 69
238000000034 method Methods 0.000 title claims description 47
238000004458 analytical method Methods 0.000 title description 31
239000003094 microcapsule Substances 0.000 claims description 46
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 43
229960005156 digoxin Drugs 0.000 claims description 43
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical group C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 43
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 43
102000004169 proteins and genes Human genes 0.000 claims description 23
108090000623 proteins and genes Proteins 0.000 claims description 23
239000012528 membrane Substances 0.000 claims description 22
238000012360 testing method Methods 0.000 claims description 19
239000000463 material Substances 0.000 claims description 14
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 13
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 11
229940034208 thyroxine Drugs 0.000 claims description 11
238000006243 chemical reaction Methods 0.000 claims description 10
230000027455 binding Effects 0.000 claims description 9
230000000295 complement effect Effects 0.000 claims description 8
239000003153 chemical reaction reagent Substances 0.000 claims description 7
108010071390 Serum Albumin Proteins 0.000 claims description 5
102000007562 Serum Albumin Human genes 0.000 claims description 5
238000009792 diffusion process Methods 0.000 claims description 5
238000000926 separation method Methods 0.000 claims description 4
229920002873 Polyethylenimine Polymers 0.000 claims description 3
230000002285 radioactive effect Effects 0.000 claims description 3
238000003018 immunoassay Methods 0.000 claims description 2
XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical group IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 claims 1
230000001939 inductive effect Effects 0.000 claims 1
229950008325 levothyroxine Drugs 0.000 claims 1
229940088597 hormone Drugs 0.000 description 41
239000005556 hormone Substances 0.000 description 41
239000000243 solution Substances 0.000 description 41
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 39
239000011521 glass Substances 0.000 description 25
239000002953 phosphate buffered saline Substances 0.000 description 21
LXEJRKJRKIFVNY-UHFFFAOYSA-N terephthaloyl chloride Chemical compound ClC(=O)C1=CC=C(C(Cl)=O)C=C1 LXEJRKJRKIFVNY-UHFFFAOYSA-N 0.000 description 19
239000002775 capsule Substances 0.000 description 16
239000012071 phase Substances 0.000 description 15
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
239000000178 monomer Substances 0.000 description 12
238000003756 stirring Methods 0.000 description 12
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
238000011534 incubation Methods 0.000 description 11
239000002904 solvent Substances 0.000 description 11
239000006228 supernatant Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
210000002966 serum Anatomy 0.000 description 9
108091003079 Bovine Serum Albumin Proteins 0.000 description 8
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
229940098773 bovine serum albumin Drugs 0.000 description 8
238000000502 dialysis Methods 0.000 description 8
230000002163 immunogen Effects 0.000 description 8
230000035699 permeability Effects 0.000 description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
229920001213 Polysorbate 20 Polymers 0.000 description 6
-1 fatty acid ester Chemical class 0.000 description 6
SYECJBOWSGTPLU-UHFFFAOYSA-N hexane-1,1-diamine Chemical compound CCCCCC(N)N SYECJBOWSGTPLU-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
238000003127 radioimmunoassay Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
238000003556 assay Methods 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
238000006116 polymerization reaction Methods 0.000 description 5
239000001267 polyvinylpyrrolidone Substances 0.000 description 5
239000004698 Polyethylene Substances 0.000 description 4
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
238000004364 calculation method Methods 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
238000002156 mixing Methods 0.000 description 4
229920000573 polyethylene Polymers 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
235000017557 sodium bicarbonate Nutrition 0.000 description 4
229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
239000000725 suspension Substances 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000012620 biological material Substances 0.000 description 3
239000000872 buffer Substances 0.000 description 3
ACWOEBLNSPFLBG-UHFFFAOYSA-N carbonic acid;hexane-1,1-diamine Chemical compound OC(O)=O.CCCCCC(N)N ACWOEBLNSPFLBG-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
229940036555 thyroid hormone Drugs 0.000 description 3
239000005495 thyroid hormone Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
102000006395 Globulins Human genes 0.000 description 2
108010044091 Globulins Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000004952 Polyamide Substances 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 2
108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 2
239000000654 additive Substances 0.000 description 2
URYUEMMCHKMUAG-UHFFFAOYSA-N carbonic acid;hexane-1,6-diamine Chemical compound OC(O)=O.NCCCCCCN URYUEMMCHKMUAG-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
238000010908 decantation Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
150000004985 diamines Chemical class 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000003517 fume Substances 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229920002647 polyamide Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000003270 steroid hormone Substances 0.000 description 2
238000010998 test method Methods 0.000 description 2
229960003604 testosterone Drugs 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
101100028791 Caenorhabditis elegans pbs-5 gene Proteins 0.000 description 1
241000282461 Canis lupus Species 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
238000012696 Interfacial polycondensation Methods 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
108010071690 Prealbumin Proteins 0.000 description 1
102000007584 Prealbumin Human genes 0.000 description 1
RXHSGRQJJBSBPN-UHFFFAOYSA-L [Na+].[Na+].Cl.OP([O-])([O-])=O Chemical compound [Na+].[Na+].Cl.OP([O-])([O-])=O RXHSGRQJJBSBPN-UHFFFAOYSA-L 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000004404 adrenal cortex Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007982 barbital buffer Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
YRUMDWGUXBZEPE-UHFFFAOYSA-N cyclohexane Chemical compound C1CCCCC1.C1CCCCC1 YRUMDWGUXBZEPE-UHFFFAOYSA-N 0.000 description 1
HASGOCLZFTZSTN-UHFFFAOYSA-N cyclohexane;hexane Chemical compound CCCCCC.C1CCCCC1 HASGOCLZFTZSTN-UHFFFAOYSA-N 0.000 description 1
230000007547 defect Effects 0.000 description 1
CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000000151 deposition Methods 0.000 description 1
230000001066 destructive effect Effects 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
229960000648 digitoxin Drugs 0.000 description 1
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000006073 displacement reaction Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000003344 environmental pollutant Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
238000009998 heat setting Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
HXUUVGVJMIBARI-UHFFFAOYSA-N hex-1-ene-1,6-diamine Chemical compound NCCCCC=CN HXUUVGVJMIBARI-UHFFFAOYSA-N 0.000 description 1
NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 1
102000036124 hormone binding proteins Human genes 0.000 description 1
108091011044 hormone binding proteins Proteins 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000002372 labelling Methods 0.000 description 1
244000144972 livestock Species 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000003550 marker Substances 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000036651 mood Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
238000005191 phase separation Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
231100000719 pollutant Toxicity 0.000 description 1
229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
229950009829 prasterone sulfate Drugs 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
CCRATEYSXZDNDF-UHFFFAOYSA-M sodium chloroform cyclohexane hydrogen carbonate Chemical compound C(Cl)(Cl)Cl.C1CCCCC1.C([O-])(O)=O.[Na+] CCRATEYSXZDNDF-UHFFFAOYSA-M 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000009987 spinning Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000010902 straw Substances 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
229940035722 triiodothyronine Drugs 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
- G01N33/5375—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by changing the physical or chemical properties of the medium or immunochemicals, e.g. temperature, density, pH, partitioning
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F02—COMBUSTION ENGINES; HOT-GAS OR COMBUSTION-PRODUCT ENGINE PLANTS
- F02B—INTERNAL-COMBUSTION PISTON ENGINES; COMBUSTION ENGINES IN GENERAL
- F02B75/00—Other engines
- F02B75/02—Engines characterised by their cycles, e.g. six-stroke
- F02B2075/022—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle
- F02B2075/025—Engines characterised by their cycles, e.g. six-stroke having less than six strokes per cycle two

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Endocrinology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

SE7905101A 1978-06-20 1979-06-12 Immunoanalysforfarande och anordning for bestemning av obundna substanser SE445680B (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US91736578A	1978-06-20	1978-06-20
US05/963,932 US4255411A (en)	1978-11-27	1978-11-27	Process of determining an immunogenic substance by competition with an antibody in a microcapsule

Publications (2)

Publication Number	Publication Date
SE7905101L SE7905101L (sv)	1979-12-21
SE445680B true SE445680B (sv)	1986-07-07

Family

ID=27129721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE7905101A SE445680B (sv)	1978-06-20	1979-06-12	Immunoanalysforfarande och anordning for bestemning av obundna substanser

Country Status (9)

Country	Link
CA (1)	CA1120397A (de)
CH (1)	CH647869A5 (de)
DE (1)	DE2924881A1 (de)
DK (1)	DK256279A (de)
FR (1)	FR2432171A1 (de)
GB (1)	GB2023816B (de)
IT (1)	IT1119920B (de)
NO (1)	NO154409C (de)
SE (1)	SE445680B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8006102L (sv) *	1980-09-02	1982-03-03	Gambro Ab	Sett att utvinna en peptidinnehallande forening samt medel for genomforande av settet
JPH0616046B2 (ja) *	1982-03-19	1994-03-02	エキンズ，ロジャーフィリップ	遊離リガンドアッセイ方法およびキット
CA2105698A1 (en) *	1992-09-16	1994-03-17	Jozsef Hepp	Label trapping assay-nonseparation binding assay method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3793445A (en) *	1970-04-29	1974-02-19	Wisconsin Alumni Res Found	Reagent for radioimmunoassay
US3896217A (en) *	1973-03-19	1975-07-22	Summa Corp	Method and apparatus for radioimmunoassay with regeneration of immunoadsorbent
US3925017A (en) *	1973-05-01	1975-12-09	Wisconsin Alumni Res Found	Preparation of dry, porous gel particles having high water regain for liquid sampling
US4061466A (en) *	1974-10-16	1977-12-06	Ingvar Gosta Holger Sjoholm	Biologically active composition and the use thereof

1979
- 1979-06-12 SE SE7905101A patent/SE445680B/sv not_active IP Right Cessation
- 1979-06-19 CA CA000330134A patent/CA1120397A/en not_active Expired
- 1979-06-19 CH CH5723/79A patent/CH647869A5/de not_active IP Right Cessation
- 1979-06-19 GB GB7921339A patent/GB2023816B/en not_active Expired
- 1979-06-19 DK DK256279A patent/DK256279A/da not_active Application Discontinuation
- 1979-06-19 IT IT68303/79A patent/IT1119920B/it active
- 1979-06-19 NO NO792030A patent/NO154409C/no unknown
- 1979-06-19 FR FR7915709A patent/FR2432171A1/fr active Granted
- 1979-06-20 DE DE19792924881 patent/DE2924881A1/de not_active Withdrawn

Also Published As

Publication number	Publication date
IT7968303A0 (it)	1979-06-19
GB2023816B (en)	1983-02-23
IT1119920B (it)	1986-03-19
FR2432171B1 (de)	1985-02-15
SE7905101L (sv)	1979-12-21
NO154409C (no)	1986-09-10
NO154409B (no)	1986-06-02
DK256279A (da)	1980-01-28
GB2023816A (en)	1980-01-03
FR2432171A1 (fr)	1980-02-22
CA1120397A (en)	1982-03-23
NO792030L (no)	1979-12-21
CH647869A5 (de)	1985-02-15
DE2924881A1 (de)	1980-01-17

Legal Events

Date

Code

Title

Description

1995-01-31

NUG

Patent has lapsed

Ref document number: 7905101-7

Effective date: 19890725

Format of ref document f/p: F

Publication	Publication Date	Title
JP2854058B2 (ja)	1999-02-03	アッセイを実施するための方法及び装置
US5759794A (en)	1998-06-02	Assay of blood or other biologic samples for target analytes
US4255411A (en)	1981-03-10	Process of determining an immunogenic substance by competition with an antibody in a microcapsule
US4138474A (en)	1979-02-06	Method and device for immunoassay
Giger et al.	2005	Comparison of various canine blood-typing methods
DE2943648A1 (de)	1980-05-14	Kombinierte heterogene spezifische bindungs-untersuchung zur gleichzeitigen bestimmung von einer mehrzahl von verschiedenen liganden in einer einzigen fluessigkeitsprobe
EP0110993A1 (de)	1984-06-20	Teilchenförmiges ligandtestverfahren, verfahren und erzeugnisse
JPS62121361A (ja)	1987-06-02	細胞集団もしくは亜集団を定量するための方法及び標準物並びに試薬キット
AU3939493A (en)	1993-11-08	Immunoassays employing generic anti-hapten antibodies and materials for use therein
AU662571B2 (en)	1995-09-07	Target component biological assay utilising liposome vesicle marker particles
BR112020016548A2 (pt)	2020-12-22	Dispositivo de diagnóstico in vitro, uso do mesmo e métodos in vitro
US4311690A (en)	1982-01-19	Test set and method for the determination of free hormones
EP0070527A1 (de)	1983-01-26	Verfahren zum Untersuchen von biologisch aktiven Substanzen und Markierungsmittel hierfür
SE448403B (sv)	1987-02-16	Anordning for genomforande av massaoverforing av en eller flera komponenter fran en forsta vetska till en andra vetska
US4278653A (en)	1981-07-14	Methods and kits for double antibody immunoassay providing a colored pellet for easy visualization
EP1064557B1 (de)	2004-05-06	Verfahren zum nachweis von antikörpern oder antigenen sowie zur blutgruppenbestimmung
SE445680B (sv)	1986-07-07	Immunoanalysforfarande och anordning for bestemning av obundna substanser
US4307071A (en)	1981-12-22	Analytical reagent and method
US4034073A (en)	1977-07-05	Composite for biased solid phase radioimmunoassay of triiodothyronine and thyroxine
JPS6231300B2 (de)	1987-07-07
US4792527A (en)	1988-12-20	Method of assaying biologically active substances and labelling agents therefor
JP3302099B2 (ja)	2002-07-15	便潜血判定装置
Halpern et al.	1979	Microencapsulated antibodies in radioimmunoassay--I. Determination of digoxin.
JP2683944B2 (ja)	1997-12-03	間接凝集免疫測定方法及び装置
CA2028995A1 (en)	1991-05-01	Indirect agglutination immunoassay and apparatus therefor